<DOC>
	<DOCNO>NCT00601406</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This clinical trial evaluate DNA mutation predict effect external-beam radiation therapy patient early breast cancer , localize prostate cancer , gynecologic cancer .</brief_summary>
	<brief_title>Study DNA Mutations Predicting Effect External-Beam Radiation Therapy Patients With Early Breast Cancer , Localized Prostate Cancer , Gynecological Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To test hypothesis association common genetic variation , report single nucleotide polymorphism ( SNP ) relevant candidate gene , associate individual patient variability normal tissue radiation response toxicity . Secondary - To compare different clinical score system late normal tissue effect , specifically Late Effect Normal Tissue Subjective Objective Management Analysis ( LENT SOMA ) , Radiation Therapy Oncology Group ( RTOG ) , quality life , subset common terminology criterion ( CTC ) version 3 . - To compare clinical score system analytical measure normal tissue outcome minority patient , use volume change breast measure laser camera . - To correlate family history information SNP analysis produce polymorphism risk score ( PRS ) family history . - To compare detailed 3D dose-volume analysis subset patient late effect SNP result . - To correlate actuarial analysis late effect change time PRS . - To conduct PRS analyse tumor control probability ( TCP ) , use survival surrogate TCP necessary , normal tissue complication vs tumor control probability . OUTLINE : This multicenter study . Patients recruit clinical trial late normal tissue effect measure . Blood sample collect patient analysis genetic variation DNA extraction single nucleotide polymorphism analysis . Sixty different gene , include involve cell cycle checkpoint control , DNA damage recognition repair , induction apoptosis , cytokine production ( include TGFÎ² pathway ) assess .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must receive curative externalbeam radiotherapy within context formal clinical study follow : Early breast cancer breastconserving surgery Localized prostate cancer Gynecological cancer ( may also receive brachytherapy ) Venous blood sample must available Patients identify follow clinical study : Cambridge intensitymodulated radiotherapy breast randomize trial RT01 prostate radiotherapy randomize trial/other prostate trial Christie hospital breast , prostate , gynecological cancer radiotherapy patient Must minimum follow late normal tissue effect score two year available PATIENT CHARACTERISTICS : No malignancy prior treatment specified tumor type except basal cell squamous cell carcinoma skin situ carcinoma PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage I vaginal cancer</keyword>
	<keyword>stage II vaginal cancer</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>stage IA vulvar cancer</keyword>
	<keyword>stage IB vulvar cancer</keyword>
	<keyword>stage II vulvar cancer</keyword>
	<keyword>stage IIIC vulvar cancer</keyword>
	<keyword>stage IIIA vulvar cancer</keyword>
	<keyword>stage IIIB vulvar cancer</keyword>
	<keyword>stage IVB vulvar cancer</keyword>
	<keyword>stage IA ovarian epithelial cancer</keyword>
	<keyword>stage IB ovarian epithelial cancer</keyword>
	<keyword>stage IC ovarian epithelial cancer</keyword>
	<keyword>stage IA ovarian germ cell tumor</keyword>
	<keyword>stage IB ovarian germ cell tumor</keyword>
	<keyword>stage IC ovarian germ cell tumor</keyword>
	<keyword>stage IIA ovarian epithelial cancer</keyword>
	<keyword>stage IIB ovarian epithelial cancer</keyword>
	<keyword>stage IIC ovarian epithelial cancer</keyword>
	<keyword>stage IIA ovarian germ cell tumor</keyword>
	<keyword>stage IIB ovarian germ cell tumor</keyword>
	<keyword>stage IIC ovarian germ cell tumor</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian germ cell tumor</keyword>
	<keyword>stage IIIB ovarian germ cell tumor</keyword>
	<keyword>stage IIIC ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>stage IA fallopian tube cancer</keyword>
	<keyword>stage IB fallopian tube cancer</keyword>
	<keyword>stage IC fallopian tube cancer</keyword>
	<keyword>stage IIA fallopian tube cancer</keyword>
	<keyword>stage IIB fallopian tube cancer</keyword>
	<keyword>stage IIC fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
	<keyword>stage IA primary peritoneal cavity cancer</keyword>
	<keyword>stage IB primary peritoneal cavity cancer</keyword>
	<keyword>stage IC primary peritoneal cavity cancer</keyword>
	<keyword>stage IIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>stage IA endometrial carcinoma</keyword>
	<keyword>stage IB endometrial carcinoma</keyword>
	<keyword>stage IIIA endometrial carcinoma</keyword>
	<keyword>stage IIIB endometrial carcinoma</keyword>
	<keyword>stage IIIC endometrial carcinoma</keyword>
	<keyword>stage IVA endometrial carcinoma</keyword>
	<keyword>stage IVB endometrial carcinoma</keyword>
	<keyword>stage IA uterine sarcoma</keyword>
	<keyword>stage IB uterine sarcoma</keyword>
	<keyword>stage IC uterine sarcoma</keyword>
	<keyword>stage IIA uterine sarcoma</keyword>
	<keyword>stage IIB uterine sarcoma</keyword>
	<keyword>stage IIIA uterine sarcoma</keyword>
	<keyword>stage IIIB uterine sarcoma</keyword>
	<keyword>stage IIIC uterine sarcoma</keyword>
	<keyword>stage IVA uterine sarcoma</keyword>
	<keyword>stage IVB uterine sarcoma</keyword>
</DOC>